» Articles » PMID: 33343895

Relationship Between and Mutations and MRNA Expression in Breast and Ovarian Cancer Predisposition

Overview
Journal Mol Clin Oncol
Specialty Oncology
Date 2020 Dec 21
PMID 33343895
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The aetiology of breast and ovarian cancer (BC/OC) is multi-factorial. At present, the involvement of base excision repair (BER) glycosylases (MUTYH and OGG1) in BC/OC predisposition is controversial. The present study investigated whether germline mutation status and mRNA expression of two BER genes, and , were correlated with in 59 patients with BC/OC and 50 matched population controls. In addition, to evaluate the relationship between , and , their possible mutual modulation and correlation among mutational spectrum, gene expression and demographic characteristics were evaluated. The results identified 18 and variants, of which 4 were novel (2 and 2 ) in 44 of the 59 patients. In addition, two pathogenic mutations were identified: p.Arg46Gln, detected in a patient with BC and a family history of cancer, and p.Val234Gly in a patient with OC, also with a family history of cancer. A significant reduced transcript expression in was observed P=0.033) in cases, and in association with the presence of rare variants in the same gene (P=0.030). A significant correlation in the expression of the two BER genes was observed in cases (P=0.004), whereas OGG1 and BRCA1 was significantly correlated in cases (P=0.001) compared with controls (P=0.010). The results of the present study indicated that the relationship among mutational spectrum, gene expression and demographic characteristics may improve the genetic diagnosis and primary prevention of at-risk individuals belonging to families with reduced mRNA expression, regardless of mutation presence.

Citing Articles

The Role of Reactive Oxygen Species in Colorectal Cancer Initiation and Progression: Perspectives on Theranostic Approaches.

Catalano T, Selvaggi F, Cotellese R, Aceto G Cancers (Basel). 2025; 17(5).

PMID: 40075600 PMC: 11899472. DOI: 10.3390/cancers17050752.


Comparison of BRCA1 Gene Expression and CA15-3 Tumor Marker Level in Different Stages of Breast Cancer.

Soltani Irdmusa N, Fakhar H, Heshmati M, Akbari M, Rahimi S Breast J. 2025; 2024:3461694.

PMID: 39742378 PMC: 11333139. DOI: 10.1155/2024/3461694.


Emerging Role of Oxidative Stress on EGFR and OGG1-BER Cross-Regulation: Implications in Thyroid Physiopathology.

Moscatello C, Di Marcantonio M, Savino L, DAmico E, Spacco G, Simeone P Cells. 2022; 11(5).

PMID: 35269445 PMC: 8909339. DOI: 10.3390/cells11050822.


Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.

Vietri M, DElia G, Caliendo G, Albanese L, Signoriello G, Napoli C Genes (Basel). 2022; 13(2).

PMID: 35205366 PMC: 8872383. DOI: 10.3390/genes13020321.


Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.

Franchet C, Hoffmann J, Dalenc F Cancers (Basel). 2021; 13(16).

PMID: 34439286 PMC: 8392832. DOI: 10.3390/cancers13164132.

References
1.
Saha T, Rih J, Rosen E . BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett. 2009; 583(9):1535-43. PMC: 2744635. DOI: 10.1016/j.febslet.2009.04.005. View

2.
Qiao L, Feng X, Wang G, Zhou B, Yang Y, Li M . Polymorphisms in BER genes and risk of breast cancer: evidences from 69 studies with 33760 cases and 33252 controls. Oncotarget. 2018; 9(22):16220-16233. PMC: 5882330. DOI: 10.18632/oncotarget.23804. View

3.
Sieber O, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips R . Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003; 348(9):791-9. DOI: 10.1056/NEJMoa025283. View

4.
Yi Y, Kang H, Bae I . BRCA1 and Oxidative Stress. Cancers (Basel). 2014; 6(2):771-95. PMC: 4074803. DOI: 10.3390/cancers6020771. View

5.
Out A, Wasielewski M, Huijts P, van Minderhout I, Houwing-Duistermaat J, Tops C . MUTYH gene variants and breast cancer in a Dutch case–control study. Breast Cancer Res Treat. 2012; 134(1):219-27. PMC: 3397219. DOI: 10.1007/s10549-012-1965-0. View